IBD highlights from the 1999 American College of Gastroenterology meeting: Infliximab and 6-MP

Inflammatory Bowel Diseases

Volumn 6, Issue 1, 2000, Pages 59-60

  Wolf, Douglas C ^a  

^a St Joseph's Medical Building III ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GASTROINTESTINAL AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; MONOCLONAL ANTIBODY;

CONFERENCE PAPER; ENTERITIS; HUMAN; TREATMENT OUTCOME;

6-MERCAPTOPURINE; ANTIBODIES, MONOCLONAL; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; TREATMENT OUTCOME;

EID: 0034132357     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1097/00054725-200002000-00011     Document Type: Article

References (5)

1. Clinical experience with infliximab therapy in 100 Crohn's disease patients. Farrell RJ, Lodhavia P, Shah S, Alsahli M, Michetti P, Peppercorn MA. Beth Israel Deaconess Medical Center, Boston, Massachusetts, and Brown University School of Medicine, Providence, Rhode Island.
2. Infliximab in Crohn's disease: first anniversary clinical experience. Cohen RD, Kisiel JB, Hanauer SB. The University of Chicago Hospitals, Chicago, Illinois.
3. Infliximab (anti-TNF alpha antibody) in treatment of rectovaginal fistulas with Crohn's disease. Ertan A, Darmadi DH. Baylor College of Medicine, The Methodist Hospital, Houston, Texas.
4. Response to Infliximab is decreased in the presence of intestinal strictures in patients with Crohn's disease. Lichtenstein GR, Stein R, Lewis JD, Deren J. University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania.
5. 6-MP metabolite levels correlate with clinical response and drug toxicity in adult IBD. Dubinsky M, Hassard P, Yang HY, Kam L, Abreu M, Seidman E, Targan S, Vasiliauskas E. Cedars-Sinai IBD Center, Los Angeles, California, and Sainte-Justine Hospital, Montreal, Canada.